Sudarshan Pharma allotted ₹96 Crore worth of FCCBs due 2029. This capital infusion strengthens liquidity and provides a route for future equity conversion.
Sudarshan Pharma approved raising up to ₹191.86 Crore through Foreign Currency Convertible Bonds. This fund-raise strengthens the company's capital base for future growth and operations.
